ACZ885
DrugACZ885 150 mg was administered subcutaneously once a month for 12 months.
Other names: Canakinumab
NCT Number: NCT00995930
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
Looking for future studies?
Notify Me18 year–74 year
All sexes
Interventional
Phase 2
Novartis Investigative Site, Montreal, Quebec, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
ACZ885 150 mg was administered subcutaneously once a month for 12 months.
Other names: Canakinumab
Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
Time frame: 12 months
Participants were monitored for adverse events, serious adverse events and death throughout the study.
Time frame: baseline, 3 months, 12 months
Two axial, ECG-gated, steady state free precession (SSFP) 'cine' images were acquired during breath-hold to determine aortic distensibility. The first image was obtained at the level of the right pulmonary artery through the ascending and proximal descending aorta and the second through the distal aorta below the diaphragm. Imaging of the aorta also enabled evaluation of the plaque burden and additional vascular function measures.
Time frame: baseline, 3 months, 12 months
For assessment of atherosclerotic plaque burden of the aorta, vessel wall images of the aorta were acquired with an ECG gated double-inversion recovery (black blood) fast spin echo sequence applied breath-holding. Using an oblique sagittal image of the aorta as a pilot, serial axial images were acquired to cover a section of the descending thoracic aorta. The midpoint of the right pulmonary artery in cross section was used as the anatomical reference for the first slice in baseline and follow-up scans. For assessment of the atherosclerotic plaque burden in the carotids, vessel wall images were acquired with an axial ECG gated PD (proton density) weighted black blood sequence. The carotid bifurcation was used as the anatomical reference for all three imaging time points (baseline, 12 weeks, 48 weeks) with axial slice planes acquired below the bifurcation region. The mean values reported here for the carotid are reported for the proximal common carotid region.
Time frame: baseline, 3 months, 12 months
Utilizing the SphygmoCor Device, ECG leads placed at the carotid and femoral arteries provided the measure of the pulse wave at that particular arterial location. The distance between the two vascular beds divided by the pulse wave time shift provided a measure of the pulse wave velocity.
Time frame: baseline, 3 months, 12 months
During the carotid MRI acquisition, in addition to the PD weighted ECG gated double inversion fast spin echo sequences T1 and T2 weighted sequences were acquired. In combination with the PD weighted images, the multi-contrast images were analyzed to determine regions of interest with contrast patterns consistent with the presence of necrotic lipid core, calcification and fibrous tissue in participants who had complex carotid plaque present in the bifurcation region.
Time frame: baseline, 3 months, 12 months
Arterial strain was computed directly from the cine SSFP images and the change in lumen diameters over the cardiac cycle. The value was independent of pulse pressure and is unitless ratio derived from the maximum to minimum lumen diameters diastole and systole, respectively..
Time frame: baseline, 3 months, 12 months
Blood samples were collected to analyze hsCRP.
Time frame: baseline, 3 months, 12 months
Blood samples were collected to analyze fasting plasma glucose.
Time frame: baseline, 3 months, 12 months
Blood samples were collected to analyze HbA1c.
Time frame: baseline, 3 months, 12 months
Blood samples were collected to analyze the 2 hour glucose post OGTT.
Time frame: baseline, 3 months, 12 months
Blood samples were collected to analyze beta cell function. Beta cell function was calculated by the Homeostasis Model Assessments (of beta cell function (HOMA-B) as follows: HOMA-B: The product of 20 and basal insulin (µU/mL) levels divided by the value of basal glucose (mmol/L) concentrations minus 3.5 [i.e., HOMA-B = 20*basal insulin/(basal glucose-3.5)].
Time frame: baseline, 3 months, 12 months
Blood samples were collected to analyze insulin resistance. Insulin resistance was calculated by the Homeostasis Model Assessments of insulin resistance (HOMA-IR)) as follows: HOMA-IR: The product of basal glucose (mmol/L) and insulin (µU/mL) levels divided by 22.5 [i.e., HOMA-IR = basal glucose*basal insulin/22.5].
Time frame: pre-dose, 0.167 day post dose 1, 7 days post dose 1, 14 days post dose 1, every 30 days post each dose from doses 1 through 12, 60 days post dose 12, 90 days post dose 12
Blood samples were collected to analyze the ACZ885 serum concentrations.
Novartis Pharmaceuticals
Industry
A Multi-center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03829982
Diabetes Mellitus, Diabetes Mellitus, Type 2
Maastricht, Limburg, Netherlands
View Trial DetailsNCT00000620
Arterial Occlusive Diseases, Arteriosclerosis
Minneapolis, Minnesota, United States
View Trial DetailsNCT00005487
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT04984421
Body Weight, Child Nutrition Disorders
Huddinge, Stockholm County, Sweden
View Trial Details